Clinical Trial Update: A Study of the Efficacy and Safety of Vernakalant Hydrochloride (MK-6621) in Patients With Atrial Fibrillation (MK-6621-010 AM4) [Phase 3]

View source ↗

Summary

A Phase 3 study assessing the efficacy and safety of vernakalant hydrochloride (MK-6621) in patients with atrial fibrillation has completed, with results posted…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atrial Fibrillation

Drugs mentioned

• Vernakalant hydrochloride (vernakalant hydrochloride)

Snippet

Sponsor: Advanz Pharma | Conditions: Atrial Fibrillation | Phase 3 | Status: COMPLETED | Results posted: 2015-12-15